Empowering plants for a healthier future

22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company focused on improving health and wellness through plant science.

Learn More

Our Companies

Read more

About Us

22nd Century Group, Inc. (Nasdaq: XXII) is a next-generation plant biotechnology company, focused on improving human health through plant science. Using our breakthrough, patent-protected IP to control nicotine biosynthesis in the tobacco plant, we have developed the first market-ready, reduced nicotine content (RNC) tobacco plants and cigarettes containing 95% less nicotine. We received the first and only FDA MRTP authorization for a combustible cigarette in December 2021. The sole function of our cigarettes is to make it easier to reduce the number of cigarettes smoked.

In tobacco, hemp/cannabis, and hop plants, 22nd Century employs a unique and innovative platform of modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding, to deliver healthier solutions for pressing issues. We create new, proprietary plants with select alkaloid, terpenoid, and flavonoid profiles, improved yields, and valuable agronomic traits for the life science and consumer products industries.


What We Do

Cigarette Dependency Reduction

Our primary mission in tobacco is to reduce the harm caused by smoking. Our VLN® reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes –  are the only non-addictive FDA-authorized cigarette designed to help smokers reduce their intake.

Read More

Hemp & Cannabis Innovation

In 2014, 22nd Century entered into a global research, licensing, IP, and commercialization agreement with Anandia Laboratories, Canada, that pushed us to the forefront of hemp/cannabis/cannabinoid research. Aurora Cannabis acquired Anandia in 2018, continuing and deepening the initial collaboration. 

Today, 22nd Century’s cannabis/hemp platform is the hub of a powerful, integrated development engine, consisting of academic, corporate, and in-house collaborations. From bioinformatics and gene editing (KeyGene) to cannabinoid effect assessment (CannaMetrix) to breeding and field testing (Extractas Bioscience) to extraction/production/packaging (GVB Biopharma), this platform can create cannabis/hemp innovations faster and with greater precision than ever before.

Read More

Hops Research

The rational, precise improvement of hops is in its infancy. However, it is a significant part of the $500 billion brewing industry and a growing source of medically useful molecules. As a close relative of cannabis/hemp, 22nd Century is well-positioned to directly and seamlessly apply its existing R&D engine to hops, accelerating the development of proprietary specialty hop varieties with valuable traits.

Read More

Our Goal

  • 134M

    Years of Life Gained

  • 8M

    Premature Deaths Avoided

  • 37%+

    Less Cigarettes Smoked Per Day

Countdown to New Zealand’s Nicotine Reduction Policy Implementation

On April 1, 2025, New Zealand will introduce new law reducing nicotine content in cigarettes to below-addictive levels.

Year 1
Month 3
Days 22